Millrace Asset Group, Inc. Vericel Corp Transaction History

Millrace Asset Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$30.93 - $59.48 $1.27 Million - $2.45 Million	-41,201 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$18.53 - $31.5 $1.72 Million - $2.92 Million	-92,645 Reduced 69.22%	41,201 $1.27 Million
Q3 2020 Nov 17, 2020	BUY	$14.68 - $19.12 $545,596 - $710,613	37,166 Added 38.44%	133,846 $2.48 Million
Q2 2020 Aug 13, 2020	SELL	$8.5 - $15.82 $448,205 - $834,188	-52,730 Reduced 35.29%	96,680 $1.34 Million
Q1 2020 May 13, 2020	BUY	$7.25 - $19.22 $859,415 - $2.28 Million	118,540 Added 384.0%	149,410 $1.37 Million
Q4 2019 Feb 13, 2020	SELL	$13.77 - $19.2 $358,143 - $499,372	-26,009 Reduced 45.73%	30,870 $537,000
Q3 2019 Nov 14, 2019	SELL	$14.93 - $19.83 $793,096 - $1.05 Million	-53,121 Reduced 48.29%	56,879 $861,000
Q2 2019 Aug 13, 2019	SELL	$15.01 - $18.89 $750,500 - $944,500	-50,000 Reduced 31.25%	110,000 $2.08 Million
Q1 2019 May 14, 2019	BUY	$16.23 - $20.29 $19,313 - $24,145	1,190 Added 0.75%	160,000 $2.8 Million
Q4 2018 Feb 13, 2019	BUY	$10.77 - $18.44 $848,783 - $1.45 Million	78,810 Added 98.51%	158,810 $2.76 Million
Q3 2018 Nov 13, 2018	BUY	$9.1 - $14.8 $728,000 - $1.18 Million	80,000 New	80,000 $1.13 Million

295

54.3M

35.6K

7.7K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $1.53B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Millrace Asset Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Millrace Asset Group, Inc. with notifications on news.